{"id":179364,"date":"2026-02-03T10:26:57","date_gmt":"2026-02-03T15:26:57","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=179364"},"modified":"2026-02-03T10:26:57","modified_gmt":"2026-02-03T15:26:57","slug":"indoco-remedies-q3-revenue-slips-as-losses-widen-despite-operating-recovery","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/indoco-remedies-q3-revenue-slips-as-losses-widen-despite-operating-recovery\/","title":{"rendered":"Indoco Remedies Q3 Revenue Slips as Losses Widen Despite Operating Recovery"},"content":{"rendered":"\n

Indoco Remedies Limited (NSE:INDOCO) <\/strong>closed at \u20b9235.00 on February 3, 2026, up 10.88% from the previous close of \u20b9211.94, surging after Q3 FY26 results announced on February 2 showed consolidated revenue of \u20b9389.6 crore (up 7% YoY) and EBITDA growth of 29% to \u20b925.9 crore despite a net loss of \u20b929.45 crore amid ongoing USFDA remediation at the Goa facility.<\/p>\n\n\n\n

Third Quarter Performance<\/strong><\/h2>\n\n\n\n

Consolidated net sales for Q3 FY2026 (December 2025 quarter) reached \u20b9445.36 crore, down 8.11% quarter-on-quarter from \u20b9484.67 crore in Q2, but up 8.48% year-on-year from \u20b9410.55 crore in Q3 FY2025. Operating profit before depreciation and interest stood at \u20b931.51 crore with a margin of 7.25%, contracting from Q2’s 9.12% despite the modest revenue growth. Net loss widened to \u20b929.79 crore from \u20b926.39 crore year-on-year, translating to a negative PAT margin of 6.78%.\u200b<\/p>\n\n\n\n

Earnings before interest, tax, depreciation and amortization expanded significantly to \u20b9315 million from \u20b9120 million year-on-year, representing 162.5% growth, though EBITDA margin remained compressed at 7.1% versus 2.93% previously. Depreciation charges of \u20b932.01 crore and elevated interest costs continued to pressure bottom-line profitability.\u200b<\/p>\n\n\n\n

Full-Year Context<\/strong><\/h2>\n\n\n\n

For fiscal year 2025, consolidated revenues totaled \u20b91,641.3 crore, reflecting an 8.4% year-on-year decline from \u20b91,789.3 crore. EBITDA contracted to \u20b999.3 crore with a margin of 6%, compared to \u20b9244.3 crore and 13.7% margin in FY2024. Full-year net loss reached \u20b973.74 crore, versus a profit of \u20b998.46 crore in FY2024.<\/p>\n\n\n\n

Regulatory and Operations Updates<\/strong><\/h2>\n\n\n\n

The company’s international formulation business remained under pressure due to ongoing remediation efforts at its Goa sterile manufacturing facility following a US Food and Drug Administration warning letter in December 2024. The FDA-inspected facility from July 16-26, 2024, had been classified with Official Action Indicated status, restricting shipments to regulated markets. Revenue from US and UK markets declined significantly throughout FY2025 due to facility disruptions.\u200b<\/p>\n\n\n\n

Positively, Indoco received final USFDA approval on January 30, 2026, for Lacosamide Oral Solution USP for epilepsy treatment, expanding its US generics portfolio in neurology. The product will be manufactured at the Verna facility in Goa, marking continued regulatory progress despite compliance challenges.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Capital and Strategic Initiatives<\/strong><\/h2>\n\n\n\n

The company incurred \u20b9264.3 crore in additional debt during FY2025 for capacity expansion and remediation. Capex focused on refurbishing manufacturing plants in Goa, Baddi, and Waluj, plus accelerated investment in wholly-owned subsidiary Warren Remedies for toothpaste and API manufacturing facilities. ICRA projects maintenance capex of \u20b950 crore in FY2026 and \u20b950-60 crore in FY2027 for Goa Plant II expansions.<\/p>\n\n\n\n

Performance Summary<\/strong><\/h2>\n\n\n\n

Indoco Remedies faced significant financial pressure in fiscal year 2025, reporting a net loss of \u20b973.74 crore as annual revenue declined by 8.4% to \u20b91,641.3 crore. While Q3 FY2026 saw a modest 8.48% year-on-year increase in consolidated net sales, net losses widened to \u20b929.79 crore amid high depreciation and interest charges. Strategically, the company incurred \u20b9264.3 crore in additional debt to fund capacity expansions at plants in Goa, Baddi, and Waluj, alongside investments in its subsidiary, Warren Remedies. Regulatory challenges persist with the Goa sterile facility under Official Action Indicated status, though the recent USFDA approval for Lacosamide Oral Solution marks a positive step for the generics portfolio. These factors contributed to a 39.4% decline in stock price from its July 2025 peak, as the market remains cautious about the pace of operational recovery and debt management.<\/p>\n","protected":false},"excerpt":{"rendered":"

Indoco Remedies Limited (NSE:INDOCO) closed at \u20b9235.00 on February 3, 2026, up 10.88% from the previous close of \u20b9211.94, surging after Q3 FY26 results announced on February 2 showed consolidated revenue of \u20b9389.6 crore (up 7% YoY) and EBITDA growth of 29% to \u20b925.9 crore despite a net loss of \u20b929.45 crore amid ongoing USFDA […]<\/p>\n","protected":false},"author":2396,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1941,5747],"tags":[10169,15642,15641,9138],"class_list":["post-179364","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock-analysis","category-healthcare-stocks","tag-earnings","tag-indoco","tag-indoco-remedies-limited","tag-pharma"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":142746,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-indoco-remedies-limited-for-q3-fy23\/","url_meta":{"origin":179364,"position":0},"title":"Earnings Summary Of Indoco Remedies Limited For Q3 FY23","author":"Hardik Bhandare","date":"February 24, 2023","format":false,"excerpt":"Indoco Remedies (NSE: INDOCO) is a leading Indian pharmaceutical company that operates in both domestic and international markets. The company has a diverse product portfolio that includes prescription drugs, over-the-counter (OTC) medicines, and veterinary products. Indoco Remedies has a strong presence in India and operates in more than 80 countries\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":149793,"url":"https:\/\/alphastreet.com\/india\/indoco-remedies-ltd-q1-fy24-38-fall-in-profits\/","url_meta":{"origin":179364,"position":1},"title":"Indoco Remedies Ltd Q1 FY24; 38% fall in Profits","author":"Hardik Bhandare","date":"July 25, 2023","format":false,"excerpt":"Indoco Remedies (Indoco) is a Mumbai-based pharmaceutical company that focuses on formulations with a presence in contract manufacturing and research. The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). Financial Results: Indoco Remedies Ltd reported Revenues for Q1FY24 of\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-191.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-191.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-191.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-191.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-191.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-191.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":155287,"url":"https:\/\/alphastreet.com\/india\/indoco-remedies-ltd-q2fy24-30-fall-in-profits\/","url_meta":{"origin":179364,"position":2},"title":"Indoco Remedies Ltd Q2FY24; 30% fall in Profits","author":"Hardik Bhandare","date":"October 25, 2023","format":false,"excerpt":"Indoco Remedies (Indoco) is a Mumbai-based pharmaceutical company that focuses on formulations with a presence in contract manufacturing and research. The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). Financial Results: Indoco Remedies Ltd reported Revenues for Q2FY24 of\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/image-111.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/image-111.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/image-111.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/image-111.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/image-111.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/image-111.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":162910,"url":"https:\/\/alphastreet.com\/india\/indoco-remedies-ltd-q4fy24-15-fall-in-profits\/","url_meta":{"origin":179364,"position":3},"title":"Indoco Remedies Ltd Q4FY24; 15% fall in Profits","author":"Divyansh_Kasana","date":"July 10, 2024","format":false,"excerpt":"Indoco Remedies (Indoco) is a Mumbai-based pharmaceutical company that focuses on formulations with a presence in contract manufacturing and research. The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). Financial Results: Indoco Remedies Ltd reported Revenues for Q4FY24 of\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-83.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-83.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-83.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-83.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-83.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-83.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":139138,"url":"https:\/\/alphastreet.com\/india\/indoco-remedies-limited-indoco-q3-fy23-earnings-concall-transcript\/","url_meta":{"origin":179364,"position":4},"title":"Indoco Remedies Limited (INDOCO) Q3 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"January 24, 2023","format":false,"excerpt":"Indoco Remedies Limited (NSE: INDOCO) Q3 FY23 Earnings Concall dated Jan. 24, 2023 Corporate Participants: Aditi Panandikar\u00a0--\u00a0Managing Director Sundeep V. Bambolkar\u00a0--\u00a0Joint Managing Director Analysts: Cyndrella Carvalho\u00a0--\u00a0JM Financial -- Analyst Aditya Khemka\u00a0--\u00a0InCred Financial Services -- Analyst Sudarshan Padmanabhan\u00a0--\u00a0JM Financial PMS -- Analyst Mitesh Shah\u00a0--\u00a0Nirmal Bang Securities -- Analyst Aejas Lakhani\u00a0--\u00a0Unifi Capital\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":179585,"url":"https:\/\/alphastreet.com\/india\/indoco-remedies-limited-indoco-q3-2026-earnings-call-transcript\/","url_meta":{"origin":179364,"position":5},"title":"Indoco Remedies Limited (INDOCO) Q3 2026 Earnings Call Transcript","author":"News desk","date":"February 4, 2026","format":false,"excerpt":"Indoco Remedies Limited (NSE: INDOCO) Q3 2026 Earnings Call dated Feb. 03, 2026 Corporate Participants: Pramod Ghorpade \u2014 President, Finance and Group Chief Financial Officer Aditi Panandikar \u2014 Managing Director Analysts: Unidentified Participant Umesh Laddha \u2014 Analyst Pratik Kothari \u2014 Analyst Kenil Mehta \u2014 Analyst Ankit Gupta \u2014 Analyst Maulik\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179364","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2396"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=179364"}],"version-history":[{"count":3,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179364\/revisions"}],"predecessor-version":[{"id":179370,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179364\/revisions\/179370"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=179364"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=179364"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=179364"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}